2nd Distributor in Canada, Entire $75m Market Now Covered
Filed with ASX · · 3 pages · English
Story so far
Earlier from Orthocell
- Remplir Launches in Hong Kong with First Surgical Case
- HK Distributor Signed as Remplir Expands in the Asian Market
- OCC Secures Rights to High-Value Bone Regeneration Tech
- $30m Placement Sees Orthocell Positioned for Rapid Growth
- Trading Halt
Later from Orthocell
- Remplir gains momentum in nerve-sparing prostate surgery
- Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide
- First Commercial Sales of Remplir Achieved in Hong Kong
- Remplir Regulatory Application for US$750m EU-UK Market
- Orthocell Hits US Milestone - 100 Remplir Units Sold.
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell